Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment
by
Aidan Kenny 1, Hazel McArdle 2, Miguel Calero 3,4
, Alberto Rabano 3,5, Stephen F. Madden 6, Kellie Adamson 2, Robert Forster 7,8, Elaine Spain 2, Jochen H.M. Prehn 1,8, David C. Henshall 1,8, Miguel Medina 3,5, Eva M. Jimenez-Mateos 9,*,† and Tobias Engel 1,8,*,†
Aidan Kenny 1, Hazel McArdle 2, Miguel Calero 3,4, Alberto Rabano 3,5, Stephen F. Madden 6, Kellie Adamson 2, Robert Forster 7,8, Elaine Spain 2, Jochen H.M. Prehn 1,8, David C. Henshall 1,8, Miguel Medina 3,5, Eva M. Jimenez-Mateos 9,*,† and Tobias Engel 1,8,*,†
1
Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin D02 YN77, Ireland
2
School of Chemical Sciences, Dublin City University, Dublin 9, Ireland
3
Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
4
Carlos III Institute of Health, 28220 Madrid, Spain
5
Centro de Investigación en Enfermedades Neurológicas (CIEN) Foundation, Queen Sofia Foundation Alzheimer Center, 28031 Madrid, Spain
6
Data Science Centre, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland
7
School of Chemical Sciences, National Centre for Sensor Research, Dublin City University, Dublin 9, Ireland
8
FutureNeuro SFI Research Centre, Dublin D02 YN77, Ireland
9
Discipline of Physiology, School of Medicine, Trinity College Dublin, The University of Dublin, Dublin D02 PN40, Ireland
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Biomolecules 2019, 9(11), 734; https://doi.org/10.3390/biom9110734
Received: 17 September 2019 / Revised: 31 October 2019 / Accepted: 9 November 2019 / Published: 13 November 2019
(This article belongs to the Section Molecular Pathology)
The need for practical biomarkers for early diagnosis of Alzheimer’s disease (AD) remains largely unmet. Here we investigated the use of blood-based microRNAs as prognostic biomarkers for AD and their application in a novel electrochemical microfluidic device for microRNA detection. MicroRNA transcriptome was profiled in plasma from patients with mild cognitive impairment (MCI) and AD. MicroRNAs Let-7b and microRNA-206 were validated at elevated levels in MCI and AD, respectively. MicroRNA-206 displayed a strong correlation with cognitive decline and memory deficits. Longitudinal follow-ups over five years identified microRNA-206 increases preceding the onset of dementia. MicroRNA-206 was increased in unprocessed plasma of AD and MCI subjects, detected by our microfluidic device. While increased Let-7b levels in plasma may be used to identify patients with MCI, changes in plasma levels of microRNA-206 may be used to predict cognitive decline and progression towards dementia at an MCI stage. MicroRNA quantification via a microfluidic device could provide a practical cost-effective tool for the stratification of patients with MCI according to risk of developing AD.
View Full-Text
Keywords:
Alzheimer’s disease; prodromal; prognosis; microRNA; microfluidic device
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Kenny, A.; McArdle, H.; Calero, M.; Rabano, A.; Madden, S.F.; Adamson, K.; Forster, R.; Spain, E.; Prehn, J.H.; Henshall, D.C.; Medina, M.; Jimenez-Mateos, E.M.; Engel, T. Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. Biomolecules 2019, 9, 734.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
- Supplementary File 1:
PDF-Document (PDF, 651 KB)
